Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Abstract : Imatinib has revolutionized the therapy of chronic myeloid leukaemia. However the complete eradication of leukaemic stem cells is still a matter of discussion. Interferon (IFN) has been used in the past with success. However the proportion of patients who achieved sustained complete cytogenetic response was small. Recently, in addition to its direct antineoplastic effect and immunomodulatory activity, IFN has been shown to stimulate the quiescent leukaemic stem cells. Thus there is now a rational for combining Imatinib and IFN. Large prospective phase III trials are in good progress to demonstrate in humans the usefullness of a combination therapy using Imatinib and IFN.
https://www.hal.inserm.fr/inserm-00441364 Contributor : Francois Guilhot-GaudeffroyConnect in order to contact the contributor Submitted on : Tuesday, December 15, 2009 - 6:42:17 PM Last modification on : Tuesday, April 19, 2022 - 10:10:42 AM Long-term archiving on: : Saturday, November 26, 2016 - 4:48:30 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
François Guilhot, Lydia Roy, Pierre-Jean Saulnier, Joëlle Guilhot. Interferon in chronic myeloid leukaemia: past and future.. Bailliè re s Best Practice and Research in Clinical Haematology, 2009, 22 (3), pp.315-29. ⟨10.1016/j.beha.2009.10.005⟩. ⟨inserm-00441364⟩